On October 12, 2026 Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), reported its participation at the 17th Annual World ADC Conference, taking place in San Diego, October 12-15, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Sutro’s presence at World ADC this year reflects meaningful progress across our pipeline, from a plenary presentation on the early clinical safety and pharmacokinetic profile of STRO-004 to new preclinical insights on STRO-006 and our first wholly-owned dual-payload ADC, STRO-227," said Hans-Peter Gerber, Ph.D., Sutro’s Chief Scientific Officer. "Notably, we look forward to sharing how the design principles that shaped STRO-004, along with our preclinical findings, are translating into its emerging clinical profile. Together, these presentations offer further evidence that our platform has the potential to deliver next-generation ADCs with a wider therapeutic index for complex targets and the ability to overcome resistance to single-payload ADCs."

Presentation/Panel Discussion Details:

Next-Generation High DAR TOPO1i x DDRi Dual-Payload ADCs to Improve Efficacy, Overcome Resistance & Enhance Safety
Presenter: Krishna Bajjuri, Ph.D.
Date/Time: October 12, 2026, 12:30PM PT

Plenary Session: Unveiling the Early Clinical Safety & PK Profile of STRO-004 to Understand How Enhanced Design & Preclinical Characterization Links to Differentiated ADC Clinical Performance

Presenter: Daniel Calarese, Ph.D.
Date/Time: October 13, 2026, 9:30AM PT
Leveraging Novel Payload MoAs & Combinations to Differentiate ADC Mechanisms & Combat Patient Resistance (Discovery Chemistry morning and afternoon sessions)
Sutro Participant (Chair): Krishna Bajjuri, Ph.D.
Date/Time: October 13, 2026, 11:00AM to 4:00PM PT
Driving Clinical Success With STRO-006: Breaking Down Insights From PDX Response & Translational Biomarkers
Presenter: Alice Yam, Ph.D.
Date/Time: October 13, 2026, 12:00PM PT

Panel: Building the Next Generation of ADC Linkers & Payloads: What do Innovators Need from Development & Manufacturing Partners?

Sutro Participant: Alice Yam, Ph.D.
Date/Time: October 13, 2026, 5:45PM PT

Breaking Down Preclinical Characterization of STRO-227 Dual Payload ADC to Evaluate Efficacy & Safety in ADC Resistance Models
Presenter: Daniel Calarese, Ph.D.
Date/Time: October 14, 2026, 2:30PM PT

Following the event, the content will be made available in the Scientific Publications section of Sutro Biopharma’s website at www.sutrobio.com.

(Press release, Sutro Biopharma, OCT 12, 2026, View Source [SID1234673328])